(12) United States Patent (10) Patent No.: US 9,358,295 B2 Tygesen Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) United States Patent (10) Patent No.: US 9,358,295 B2 Tygesen Et Al US009358295R2 (12) United States Patent (10) Patent No.: US 9,358,295 B2 Tygesen et al. (45) Date of Patent: *Jun. 7, 2016 (54) IMMEDIATE RELEASE COMPOSITION (56) References Cited RESISTANT TO ABUSEBY INTAKE OF ALCOHOL U.S. PATENT DOCUMENTS 2,685,553 A 8, 1954 Carroll et al. (71) Applicant: Egalet Ltd., London (GB) 3,835,221 A 9, 1974 Fulberth et al. 3,957,523 A 5, 1976 Ohno et al. (72) Inventors: Peter Holm Tygesen, Smoerum (DK), 4,330,3384,034,758 A 7,5, 19821977 TheeuwesBanker Jan Martin Oevergaard, Frederikssund 4.389,393 A 6, 1983 Schor et al. (DK); Joakim Oestman, Lomma (SE) 4.404,183 A 9, 1983 Kawata et al. 4,449,983 A 5/1984 Cortese et al. 4,503,067 A 3, 1985 Wiedemann et al. (73) Assignee: EGALET LTD., London (GB) 4,686,212 A 8, 1987 Ducatman et al. 4,824,675 A 4/1989 Wong et al. (*) Notice: Subject to any disclaimer, the term of this is: A 6. 3. Esthetricklet al. al. past list: sited under 35 4,892,742 A 1/1990 Shah M YW- 4,898,733. A 2f1990 De Prince et al. This patent is Subject to a terminal disis- 5,068,1125,019,396 A 1 5/19911/1991 SamejimaAyer et al. et al. claimer. 5,082,655 A 1/1992 Snipes et al. 5,102,668 A 4, 1992 Eichel et al. 5,213,808 A 5/1993 Bar-Shalom et al. (21) Appl. No.: 14/656,016 5,266,331 A 11/1993 Oshlack et al. 5,281,420 A 1/1994 Kelmet al. (22) Filed: Mar 12, 2015 5,352.455 A 10, 1994 Robertson 5,411,745 A 5/1995 Oshlack et al. (65) Prior Publication Data 5.432.1335.419,917. A 6/19955/1995 ConteChen et et al. al. 5,460,826 A 10, 1995 Merrill et al. US 2015/0313997 A1 Nov. 5, 2015 5,478,577 A 12/1995 Sackler et al. 5,508,042 A 4/1996 OShlack et al. 5,520,931 A 5/1996 Persson et al. Related U.S. Application Data 5,529,787 A 6/1996 Merrill et al. 5,549,912 A 8, 1996 OShlack et al. (63) Continuation of application No. 12/701.248, filed on 5,593,695 A 1/1997 Merrill et al. Feb. 5, 2010, now Pat. No. 9,005.660 5,609,885. A 3/1997 Rivera et al. s s vs.- ... -- w w / w w 5,614,218 A 3, 1997 Olsson et al. (60) Provisional application No. 61/150,577, filed on Feb. 5,618,560 A 4/1997 Bar-Shalom et al. 6, 2009, provisional application No. 61/151.491, filed 5,656,291 A 8, 1997 Olsson et al. on Feb. 10, 2009. (Continued) (30) Foreign Application Priority Data FOREIGN PATENT DOCUMENTS EP O435,726 8, 1991 Feb. 6, 2009 (DK) ................................. 2009 OO190 EP O493513 7, 1992 (Continued) (51) Int. Cl. A6 IK9/46 (2006.01) OTHER PUBLICATIONS A6 IK 9/16 (2006.01) U.S. Appl. No. 13/900,933, filed Aug. 25, 2006, Purdue Pharma C. A6 IK3I/44 (2006.01) Bravo et al., “In-vitro studies of diclofenac sodium controlled-release A6 IK3I/6 (2006.01) from biopolymeric hydrophilic matrices.” J. Pharmaceutical Sci A6 IK3I/485 (2006.01) ence, vol. 5, No. 3, pp. 213-219 (2002). A6 IK3I/67 (2006.01) The Condensed Chemical Dictionary, “mixture.” 9th edition, p. 584 A6 IK 9/28 (2006.01) (1977). A6 IK9/20 (2006.01) Giunchedi et al "Hydrophilic matrices for the extended release of a A6 IK 47/10 (2006.01) model drug exhibiting pH-dependent solubility.” International Jour A6 IK 47/02 (2006.01) nal of Pharmaceutics, vol. 85, pp. 141-147 (1992). A6 IK 47/12 (2006.01) (Continued) (52) U.S. Cl. CPC ............... A61K 47/10 (2013.01); A61 K9/0007 Primary Examiner — Shirley V Gembeh (2013.01); A61 K9/2031 (2013.01); A61 K (74) Attorney, Agent, or Firm — Foley & Lardner LLP 9/2866 (2013.01); A61 K9/2893 (2013.01); A61 K3I/I67 (2013.01); A61 K3I/485 (57) ABSTRACT (2013.01); A61 K47/02 (2013.01); A61 K47/12 The present invention provides immediate release pharma (2013.01); A61 K9/2095 (2013.01) ceutical compositions for oral administration that are resis (58) Field of Classification Search tant to abuse by intake of alcohol. USPC ........................... 424/466,495; 514/282, 629 See application file for complete search history. 19 Claims, 23 Drawing Sheets US 9,358,295 B2 Page 2 (56) References Cited 7,510,727 B2 3, 2009 Oshlack et al. 7,514,100 B2 4/2009 Oshlack et al. U.S. PATENT DOCUMENTS 7,666,337 B2 2, 2010 Yang et al. 7,749,542 B2 T/2010 Kaiko et al. 5,656,295 8, 1997 Oshlack et al. 7,771,707 B2 8, 2010 Hirsh et al. 5,667,805 9, 1997 Merrill et al. 7,776,314 B2 8, 2010 Bartholomaus et al. 5,672,360 9, 1997 Sackler et al. 7,842,307 B2 11, 2010 Oshlack et al. 5,741,524 4, 1998 Staniforth et al. 7,846,476 B2 12/2010 Oshlack et al. 5,866, 161 2, 1999 Childers et al. 7,883,722 B2 2, 2011 Bar-Shalom 5,866, 164 2, 1999 Kuczynski et al. 7,883,772 B2 2, 2011 Pourdeyhimi et al. 5,869,097 2, 1999 Wong et al. 7,897,080 B2 3, 2011 Yang et al. 5,879,705 3, 1999 Heafield et al. 7,906, 143 B1 3, 2011 Odidi et al. 5,882,682 3, 1999 Rork et al. 7,943,174 B2 5, 2011 Oshlack et al. 5,914, 131 6, 1999 Merrill et al. 7968,120 B2 6, 2011 Li et al. 5.948,787 9, 1999 Merrill et al. 7.972,624 B2 T/2011 Li et al. 5,952,005 9, 1999 Olsson et al. 7,981,439 B2 T/2011 Kumar et al. 5,968,551 10, 1999 Oshlack et al. 8,017,148 B2 9, 2011 Sackler 6,046,177 4, 2000 Stella et al. 8,017,150 B2 9, 2011 Yang et al. 6,066,339 5, 2000 Stark et al. 8,029,822 B2 10, 2011 Faour et al. 6,077,533 6, 2000 Oshlack et al. 8,075,872 B2 12/2011 Arkenau-Marie et al. 6,077,538 6, 2000 Merrill et al. 8, 101,630 B2 1, 2012 Kumar et al. 6,103.261 8, 2000 Chasin et al. 8, 105,631 B2 1, 2012 Kaiko et al. 6,117,453 9, 2000 Seth et al. 8,114,383 B2 2, 2012 Bartholomaus et al. 6,143,328 11, 2000 Heafield et al. 8,114,384 B2 2, 2012 Arkenau et al. 6,183,778 2, 2001 Conte et al. 8,133,507 B2 3, 2012 Yum et al. 6,225,343 5, 2001 Behlet al. 8,142,811 B2 3, 2012 Oshlack et al. 6,245,351 6, 2001 Nara et al. 8, 147,870 B2 4, 2012 Yum et al. 6,245,357 6, 2001 Edgren et al. 8,153,152 B2 4, 2012 Yum et al. 6,267.981 T/2001 Okamoto et al. 8,168.217 B2 5, 2012 Yum et al. 6,267,985 T/2001 Chen et al. 8,173,152 B2 5, 2012 Crowley et al. 6,277,384 8, 2001 Kaiko et al. 8, 182,836 B2 5, 2012 Mehta 6,284.274 9, 2001 Merrill et al. 8, 192,722 B2 6, 2012 Arkenau-Maric et al. 6,294,195 9, 2001 Oshlack et al. 8,231,898 B2 T/2012 Oshlack et al. 6,348,216 2, 2002 Kushla et al. 8,246,986 B2 8, 2012 Cruz et al. 6,375,957 4, 2002 Kaiko et al. 8,309,060 B2 11, 2012 Bartholomaus et al. 6,383,471 5, 2002 Chen et al. 8.323,889 B2 12/2012 Arkenau-Maric et al. 6,395,299 5/2002 Babich et al. 8,329.720 B1 12, 2012 King et al. 6,399,096 6, 2002 Miller et al. 8,337,888 B2 12/2012 Wright et al. 6,403,579 6, 2002 Heller 8.338,444 B1 12/2012 King et al. 6,451,848 9, 2002 Behlet al. 8,354,124 B2 1, 2013 Yum et al. 6.458,772 10, 2002 Zhou et al. 8,361,499 B2 1, 2013 Oshlack et al. 6,458,824 10, 2002 Iwata et al. 8,367,693 B1 2, 2013 King et al. 6,475,494 11, 2002 Kaiko et al. 8,372.432 B2 2, 2013 Han et al. 6,482.437 11, 2002 Debregeas et al. 8,377,453 B2 2, 2013 Han et al. 6,488,962 12, 2002 Berner et al. 8,383,152 B2 2, 2013 Jans et al. 6,488.963 12, 2002 McGinity et al. 8,383,154 B2 2, 2013 Bar-Shalom 6,491,945 12, 2002 Childers et al. 8,383,155 B2 2, 2013 Bar-Shalom 6,517,866 2, 2003 Am Ende et al. 8,389,007 B2 3, 2013 Wright et al. 6,534,085 3, 2003 Zeligs 8,394.407 B2 3, 2013 Vergnault et al. 6,543,085 4, 2003 Holsten et al. 8,394.408 B2 3, 2013 Han et al. 6,562.375 5/2003 Sako et al. 8,409,616 B2 4, 2013 Kumar et al. 6,572.885 6, 2003 Oshlack et al.
Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Sectionpm E] Analytical Кгейг“' Control Radiopharmaceuticals
    section P m e ] Analytical кгейг“' Control i - ¡ Q f Radiopharmaceuticals Proceedings of a Panel Vienna, • ° 7-11 July 1969 INTERNATIONAL ATOMIC ENERGY AGENCY, VIENNA, 1970 ANALYTICAL CONTROL OF RADIOPHARMACEUTICALS The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GREECE .NORWAY ALBANIA GUATEMALA PAKISTAN ALGERIA HAITI PANAMA ARGENTINA HOLY SEE PÂRAGUAY AUSTRALIA HUNGARY PERU AUSTRIA ICELAND PHILIPPINES BELGIUM INDIA POLAND BOLIVIA INDONESIA PORTUGAL BRAZIL IRAN ROMANIA BULGARIA IRAQ' SAUDI ARABIA BURMA IRELAND SENEGAL BYELORUSSIAN SOVIET ISRAEL SIERRA LEONE SOCIALIST REPUBLIC ITALY SINGAPORE CAMBODIA IVORY COAST SOUTH AFRICA CAMEROON JAMAICA SPAIN CANADA JAPAN SUDAN CEYLON JORDAN SWEDEN CHILE KENYA SWITZERLAND CHINA KOREA, REPUBLIC OF SYRIAN ARAB REPUBLIC COLOMBIA KUWAIT THAILAND CONGO, DEMOCRATIC LEBANON TUNISIA REPUBLIC OF LIBERIA TURKEY COSTA RICA LIBYAN ARAB REPUBliC UGANDA CUBA LIECHTENSTEIN UKRAINIAN'SOVIET SOCIALIST CYPRUS LUXEMBOURG REPUBLIC CZECHOSLOVAK SOCIALIST MADAGASCAR UNION OF SOVIET SOCIALIST REPUBLIC MALAYSIA REPUBLICS DENMARK MALI UNITED ARAB REPUBLIC DOMINICAN REPUBLIC MEXICO UNITED KINGDOM OF GREAT ECUADOR MONACO BRITAIN AND NORTHERN EL SALVADOR MOROCCO IRELAND ETHIOPIA NETHERLANDS UNITED STATES OF AMERICA FINLAND NEW ZEALAND URUGUAY FRANCE NICARAGUA VENEZUELA GABON NIGER VIET-NAM GERMANY, FEDERAL REPUBLIC OF NIGERIA YUGOSLAVIA GHANA *• ZAMBIA The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters,
    [Show full text]
  • Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease
    International Journal of Molecular Sciences Review Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease Michiel Van Bulck 1,2 , Ana Sierra-Magro 1,2, Jesus Alarcon-Gil 1, Ana Perez-Castillo 1,2 and Jose A. Morales-Garcia 1,2,3,* 1 Instituto de Investigaciones Biomédicas (CSIC-UAM), Arturo Duperier, 4. 28029 Madrid, Spain; [email protected] (M.V.B.); [email protected] (A.S.-M.); [email protected] (J.A.-G.); [email protected] (A.P.-C.) 2 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo, 5, 28031 Madrid, Spain 3 Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain * Correspondence: [email protected] Received: 31 December 2018; Accepted: 3 February 2019; Published: 8 February 2019 Abstract: Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • PDF Download
    CURRENT THERAPEUTIC RESEARCH VOL. 56, NO. 5, MAY 1995 EFFECTS OF CEREBRAL METABOLIC ENHANCERS ON BRAIN FUNCTION IN RODENTS KOICHIRO TAKAHASHI,l MINORU YAMAMOTO,’ MASANORI SUZUKI,’ YUKIKO OZAWA,’ TAKASHI YAMAGUCHI,l HIROFUMI ANDOH, AND KOUICHI ISHIKAWA2 ‘Department of Pharmacology, Clinical Pharmacology Research Laboratory, Yamunouchi Pharmaceutical Co. Ltd., and ‘Department of Pharmacology, School of Medicine, Nihon University, Tokyo, Japan AFWI’RACT The effects of cerebral metabolic enhancers (indeloxazine, bi- femelane, idebenone, and nicergoline) on reserpine-induced hypother- mia, the immobility period in forced swimming tests, and passive avoidance learning behavior were compared with the effects of ami- triptyline in rodents. Indeloxazine, bifemelane, and amitriptyline antagonized hypothermia in mice given reserpine. Indeloxaxine and amitriptyline decreased the immobility period in mice in the forced swimming test in a dose-dependent manner. The latency of step- through in the passive avoidance test in rats was prolonged by ad- ministration of indeloxazine but shortened by administration of amitriptyline. Neither idebenone nor nicergoline displayed any phar- macologic action in these tests. The results suggest that indeloxaxine possesses an antidepressant activity similar to that of amitriptyline but differs from amitriptyline in its anticholinergic properties and its ability to ameliorate impaired brain function such as that of learning behavior. In addition, indeloxazine exhibited broader effects on brain functions than either bifemelane, idebenone, or nicergoline. INTRODUCTION Cerebral metabolic enhancers (drugs that enhance energy metabolism) including brain glucose and ATP levels such as indeloxazine,1*2 bi- femelane, 3*4idebenone?6 and nicergoline,7>8 are currently used for the treatment of patients with various psychiatric symptoms. These symptoms include reduced spontaneity and emotional disturbance in patients with cerebral vascular disease.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]